Sarepta Therapeutics stock forecast
Sarepta Therapeutics (AB3A) Stock Forecast & Price Target
AB3A Analyst Ratings
AB3A Stock 12 Month Forecast
Average Price Target
CHF17.99▲(0.00% Upside)Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Biren Amin | Piper Sandler | CHF16.71 | hold | ― | Reiterated | 11/13/26 | ||
| David Hoang | Deutsche Bank | CHF15.04 | hold | ― | Upgraded | 11/10/26 | ||
| Eliana Merle | Barclays | CHF16.71 | hold | ― | Reiterated | 11/09/26 | ||
| Yigal Nochomovitz | Citi | CHF10.86 | sell | ― | Reiterated | 11/09/26 | ||
| Brian Skorney | Robert W. Baird | CHF16.71→CHF15.04 | hold | ― | Reiterated | 11/06/26 | ||
| Mitchell Kapoor | H.C. Wainwright | CHF4.18 | sell | ― | Reiterated | 11/06/26 | ||
| Yanan Zhu | Wells Fargo | CHF31.74 | buy | ― | Reiterated | 11/06/26 | ||
| Kostas Biliouris | Oppenheimer | CHF29.24 | buy | ― | Reiterated | 11/06/26 | ||
| Yun Zhong | Wedbush | CHF29.24 | buy | ― | Reiterated | 11/06/26 | ||
| Michael Ulz | Morgan Stanley | CHF20.88 | hold | ― | Assigned | 11/06/26 | ||
| Tazeen Ahmad | Bank of America Securities | ― | sell | ― | Reiterated | 11/06/26 | ||
| Brian Abrahams | RBC Capital | CHF14.20→CHF15.04 | hold | ― | Reiterated | 11/05/26 | ||
| Kristen Kluska | Cantor Fitzgerald | CHF17.54 | hold | ― | Reiterated | 11/05/26 | ||
| Ritu Baral | TD Cowen | CHF14.20 | hold | ― | Reiterated | 10/21/26 | ||
| Leerink Partners | CHF16.71 | hold | ― | Reiterated | 10/15/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Biren AminPiper Sandler | HoldReiteratedCHF16.71 | 11/13/26 | ― | ||
| David HoangDeutsche Bank | HoldUpgradedCHF15.04 | 11/10/26 | ― | ||
| Eliana MerleBarclays | HoldReiteratedCHF16.71 | 11/09/26 | ― | ||
| Yigal NochomovitzCiti | SellReiteratedCHF10.86 | 11/09/26 | ― | ||
| Brian SkorneyRobert W. Baird | HoldReiteratedCHF16.71→CHF15.04 | 11/06/26 | ― | ||
| Mitchell KapoorH.C. Wainwright | SellReiteratedCHF4.18 | 11/06/26 | ― | ||
| Yanan ZhuWells Fargo | BuyReiteratedCHF31.74 | 11/06/26 | ― | ||
| Kostas BiliourisOppenheimer | BuyReiteratedCHF29.24 | 11/06/26 | ― | ||
| Yun ZhongWedbush | BuyReiteratedCHF29.24 | 11/06/26 | ― | ||
| Michael UlzMorgan Stanley | HoldAssignedCHF20.88 | 11/06/26 | ― | ||
| Tazeen AhmadBank of America Securities | SellReiterated | 11/06/26 | ― | ||
| Brian AbrahamsRBC Capital | HoldReiteratedCHF14.20→CHF15.04 | 11/05/26 | ― | ||
| Kristen KluskaCantor Fitzgerald | HoldReiteratedCHF17.54 | 11/05/26 | ― | ||
| Ritu BaralTD Cowen | HoldReiteratedCHF14.20 | 10/21/26 | ― | ||
| HoldReiteratedCHF16.71 | 10/15/26 | ― |
Best Analysts Covering Sarepta Therapeutics
Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 84.21% of your transactions generating a profit, with an average return of +12.34% per trade.
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +23.08% per trade.
Copying Mitchell Kapoor's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +25.01% per trade.
AB3A Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 6 | 8 | 8 |
| Buy | 2 | 1 | 1 | 0 | 0 |
| Hold | 13 | 13 | 15 | 17 | 18 |
| Sell | 4 | 4 | 6 | 5 | 6 |
| Strong Sell | 3 | 3 | 4 | 5 | 5 |
| total | 28 | 26 | 32 | 35 | 37 |
In the current month, AB3A has received 8 Buy Ratings, 18 Hold Ratings, and 11 Sell Ratings. AB3A average Analyst price target in the past 3 months is 17.99.
AB3A Financial Forecast
AB3A Earnings Forecast
Next quarter’s earnings estimate for AB3A is -CHF 0.30 with a range of -CHF 1.30 to CHF 0.17. The previous quarter’s EPS was -CHF 0.23. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
AB3A Sales Forecast
Next quarter’s sales forecast for AB3A is CHF 296.13M with a range of CHF 251.23M to CHF 325.12M. The previous quarter’s sales results were CHF 318.54M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

